Evaluating the Effectiveness of Psychedelic Therapies

Psychedelic therapies have re-emerged as a promising approach in the treatment of various psychological conditions, including depression, anxiety, PTSD, and addiction. This article evaluates the effectiveness of psychedelic-assisted therapies, drawing on contemporary research and clinical trials involving substances such as MDMA, psilocybin, and ketamine. Through an analysis of their therapeutic efficacy, mechanisms of action, and integration into modern psychological practice, the article also addresses the challenges inherent in studying these treatments, including methodological, ethical, and legal considerations. The exploration highlights both the potential and limitations of psychedelics within the framework of mental health care, offering a comprehensive understanding of their role in transpersonal psychology.

Introduction

The use of psychedelic substances as a form of therapy has gained significant attention in recent years, largely due to the growing body of research suggesting their potential to treat a variety of mental health disorders. Psychedelic-assisted therapy involves the controlled use of psychoactive substances such as psilocybin, MDMA, and ketamine under the guidance of trained professionals. These substances are believed to facilitate altered states of consciousness that may help individuals process traumatic experiences, gain insight into their psychological challenges, and foster emotional healing (Schenberg, 2018). While psychedelic substances were once dismissed as dangerous or counterproductive due to their association with the counterculture of the 1960s, recent scientific studies have sparked renewed interest, positioning these therapies as a cutting-edge approach within the broader context of transpersonal psychology.

The resurgence of psychedelic therapy can be attributed to successful clinical trials demonstrating their effectiveness in treating conditions that are often resistant to conventional therapies, such as treatment-resistant depression, post-traumatic stress disorder (PTSD), and addiction (Carhart-Harris et al., 2016). These therapies provide patients with opportunities to confront deep-seated emotional and psychological trauma in a controlled, therapeutic environment. Researchers believe that psychedelics, when combined with psychotherapy, can enhance emotional processing, promote neuroplasticity, and catalyze profound personal transformation. For instance, psilocybin has been found to significantly reduce symptoms of depression and anxiety in patients facing life-threatening illnesses, while MDMA-assisted therapy has shown promise in alleviating PTSD symptoms in war veterans and survivors of childhood trauma (Mithoefer et al., 2018).

Despite these promising results, the use of psychedelic-assisted therapies remains controversial. Legal and regulatory restrictions pose significant barriers to widespread clinical adoption, and ethical concerns regarding their safety persist, particularly when it comes to vulnerable populations. Moreover, the subjective nature of psychedelic experiences makes it difficult to measure therapeutic outcomes with precision, raising questions about the generalizability of current research findings (Nutt et al., 2020). Nonetheless, the growing body of evidence supporting psychedelic therapies highlights their potential to transform mental health care and urges further exploration into their efficacy and safety.

Historical and Contemporary Context of Psychedelic Therapies

Early Research and Indigenous Use

Psychedelic substances have been used for millennia by indigenous cultures in religious and healing rituals, long before they became a subject of Western scientific inquiry. Substances such as psilocybin, found in certain species of mushrooms, and ayahuasca, a brew used in Amazonian shamanic traditions, have played central roles in spiritual and healing practices (Metzner, 2017). These cultures believed that such substances facilitated communication with spiritual realms and promoted mental and physical healing through profound insights and visions (Labate & Cavnar, 2014). The use of these substances was typically guided by a shaman or spiritual leader who helped participants interpret their experiences, ensuring that the altered states of consciousness were integrated into their daily lives.

In Western science, interest in psychedelics emerged in the mid-20th century with the discovery of lysergic acid diethylamide (LSD) by Swiss chemist Albert Hofmann in 1938. During the 1950s and 1960s, researchers began to explore the therapeutic potential of psychedelics, particularly in treating mental health conditions such as anxiety, depression, and addiction (Hofmann, 2013). LSD, in particular, was studied extensively in clinical settings, with initial findings suggesting that it could catalyze profound psychological insights and emotional breakthroughs, facilitating long-term recovery from these conditions (Grinspoon & Bakalar, 1979). However, as these substances gained popularity in the countercultural movements of the 1960s, their association with recreational use led to increased scrutiny and political backlash.

The criminalization of psychedelic substances in the late 1960s and early 1970s marked the end of this initial wave of research. The U.S. government, concerned about the growing influence of the counterculture and its association with drug use, classified LSD and other psychedelics as Schedule I drugs, indicating that they had no accepted medical use and a high potential for abuse (Pollan, 2018). This decision effectively halted all clinical research into the therapeutic potential of psychedelics for several decades. Despite this, indigenous use of psychedelics continued in traditional contexts, while underground therapists and researchers persisted in using these substances for psychological healing, albeit without the legitimacy of formal scientific approval.

Integration into Modern Psychological Practice

The resurgence of interest in psychedelics in the 21st century has led to a renaissance in research, with studies now exploring their potential benefits in treating a wide range of mental health conditions. This shift can largely be attributed to advancements in neuroscience, which have helped explain how psychedelics influence the brain’s chemistry and structure. Modern studies have shown that psychedelics such as psilocybin and MDMA promote neuroplasticity, or the brain’s ability to form new neural connections, thereby enhancing emotional and cognitive flexibility (Ly et al., 2018). These insights have prompted the integration of psychedelics into modern psychological practice, where they are used as adjuncts to psychotherapy to help individuals access and process repressed emotions and traumas.

The reintroduction of psychedelics into clinical settings has been marked by rigorous safety protocols and careful patient selection. Psychedelic-assisted psychotherapy typically involves multiple stages: preparation, the administration of the psychedelic substance under controlled conditions, and post-session integration, where patients work with therapists to make sense of their experiences (Johnson et al., 2019). In contrast to traditional psychotherapy, psychedelic therapy allows patients to experience profound shifts in consciousness that can lead to rapid psychological breakthroughs, particularly for conditions that have proven resistant to other forms of treatment, such as treatment-resistant depression and PTSD (Griffiths et al., 2016). These therapeutic sessions are carefully monitored, with a focus on “set and setting”—the mental state of the patient and the physical environment—both of which are considered crucial to the success of the therapy.

A significant development in the modern use of psychedelics is the increasing institutional support for research. Leading institutions, such as Johns Hopkins University and Imperial College London, have established dedicated centers for psychedelic research, reflecting the growing legitimacy of this field within mainstream medicine and psychology (Nichols et al., 2017). These institutions have been at the forefront of clinical trials investigating the use of psilocybin, MDMA, and other psychedelics in treating mental health disorders. As these studies gain wider recognition, there is growing momentum for regulatory changes that may one day allow psychedelics to be legally prescribed in therapeutic contexts, provided their efficacy and safety continue to be validated.

Efficacy of Psychedelic Therapies for Various Psychological Conditions

Depression and Anxiety

Psychedelic therapies have shown significant promise in treating depression, particularly treatment-resistant depression (TRD), a condition that affects individuals who do not respond to conventional antidepressants. Psilocybin, the active compound in certain species of mushrooms, has been at the forefront of this research. Studies indicate that psilocybin, when combined with psychological support, can induce rapid and sustained reductions in depressive symptoms. Carhart-Harris et al. (2016) conducted a landmark trial showing that a single high-dose psilocybin session, coupled with psychotherapy, produced substantial improvements in TRD patients, with many reporting reductions in depressive symptoms for up to six months. This effect is believed to be due to psilocybin’s ability to disrupt negative thought patterns by promoting greater cognitive and emotional flexibility, facilitated through its action on serotonin receptors.

Anxiety, particularly in the context of life-threatening illnesses, has also been a key target of psychedelic therapies. Clinical trials involving terminally ill cancer patients have demonstrated that psilocybin can reduce existential anxiety and depression. Griffiths et al. (2016) found that a single psilocybin session significantly improved mood and reduced anxiety in these patients, effects that were sustained for several months. Unlike traditional anxiolytic medications, which can dull emotional responses, psilocybin appears to facilitate deep emotional processing, allowing patients to confront their fears of death and mortality. This has led researchers to propose that psychedelics offer a unique therapeutic pathway by helping individuals attain a sense of meaning and spiritual well-being, which can be pivotal in alleviating existential distress (Ross et al., 2016).

Another important aspect of psychedelic therapy for depression and anxiety is its capacity to induce mystical-type experiences. These experiences, characterized by feelings of unity, transcendence, and profound connection to life, are strongly correlated with positive therapeutic outcomes (Griffiths et al., 2008). In contrast to conventional treatments that target symptoms directly, psychedelics appear to work by fostering a transformative inner experience that allows patients to shift their perspective on their condition. This marks a departure from the purely pharmacological approach of symptom suppression and highlights the potential for psychedelics to offer holistic healing for emotional and existential suffering.

Post-Traumatic Stress Disorder (PTSD)

Psychedelic-assisted psychotherapy has also shown remarkable efficacy in treating post-traumatic stress disorder (PTSD), particularly through the use of MDMA (3,4-methylenedioxymethamphetamine). PTSD is a debilitating condition characterized by intrusive memories, hyperarousal, and emotional numbing, often resulting from severe trauma such as combat, sexual assault, or childhood abuse. Traditional psychotherapeutic approaches, such as cognitive-behavioral therapy (CBT), are often limited by patients’ reluctance to confront traumatic memories. MDMA-assisted psychotherapy offers a promising alternative by reducing fear and increasing emotional openness, which facilitates deeper engagement with traumatic memories (Mithoefer et al., 2018).

Clinical trials have demonstrated the effectiveness of MDMA-assisted therapy in significantly reducing PTSD symptoms. In phase 2 trials, conducted by Mithoefer et al. (2011), two-thirds of participants no longer met the diagnostic criteria for PTSD after completing MDMA-assisted psychotherapy, and these results were sustained in follow-up assessments a year later. The neurobiological mechanisms underlying MDMA’s therapeutic effects are linked to its action on serotonin and oxytocin systems, which increase feelings of trust and safety while reducing fear-related brain activity in the amygdala (Jerome et al., 2020). This unique combination allows patients to revisit traumatic memories without being overwhelmed by fear, enabling emotional processing and resolution of trauma.

The potential for MDMA-assisted therapy to revolutionize PTSD treatment is particularly significant given the chronic and often treatment-resistant nature of the disorder. While traditional medications, such as selective serotonin reuptake inhibitors (SSRIs), can alleviate symptoms, they rarely address the root causes of PTSD. MDMA-assisted therapy, on the other hand, has the potential to catalyze profound therapeutic breakthroughs by allowing patients to engage with and process their trauma in ways that were previously inaccessible. As research continues to advance, MDMA therapy is poised to become a powerful tool in the treatment of trauma-related disorders, pending regulatory approval.

Addiction Treatment

Addiction is another area where psychedelic therapies have shown promising results. Classical psychedelics, such as psilocybin and LSD (lysergic acid diethylamide), have been studied for their potential to break the cycle of addiction by promoting transformative experiences that lead to long-lasting behavioral change. Early research on LSD in the 1950s and 1960s suggested that it could help individuals overcome alcohol addiction, but this line of inquiry was largely abandoned following the criminalization of psychedelics. However, recent studies have reignited interest in the use of psychedelics for addiction treatment, particularly with psilocybin (Bogenschutz et al., 2015).

Psilocybin-assisted therapy has been shown to produce substantial reductions in alcohol and nicotine dependence. In a pilot study by Johnson et al. (2014), psilocybin was used to treat nicotine addiction, with 80% of participants achieving smoking cessation after one year, a rate significantly higher than conventional treatments. Similarly, Bogenschutz et al. (2015) demonstrated that psilocybin-assisted therapy led to significant reductions in alcohol consumption among individuals with alcohol use disorder. The efficacy of psychedelics in treating addiction is believed to stem from their ability to disrupt habitual patterns of thought and behavior, allowing individuals to gain new perspectives on their substance use and motivation for change (Garcia-Romeu et al., 2014).

One of the key mechanisms through which psychedelics facilitate addiction recovery is by inducing experiences of self-transcendence and interconnectedness, which can foster a sense of meaning and purpose that may be absent in individuals struggling with addiction. These transformative experiences often lead to a reevaluation of life goals and priorities, motivating individuals to pursue healthier, more fulfilling lives (Garcia-Romeu et al., 2014). As a result, psychedelic-assisted therapies represent a novel approach to addiction treatment, offering a more holistic path to recovery compared to conventional pharmacotherapies that primarily address withdrawal symptoms and cravings.

Methodological Considerations in Psychedelic Therapy Research

Challenges in Study Design and Placebo Control

Research on psychedelic therapies faces significant methodological challenges, particularly in the design of clinical trials. One of the primary obstacles is the difficulty of implementing double-blind, placebo-controlled studies, which are the gold standard in clinical research. Psychedelics induce highly distinctive and intense psychological effects, making it difficult to design a placebo that adequately mimics these experiences without producing the same therapeutic outcomes. Studies using low doses of psychedelics as a placebo often struggle to maintain the blinding of participants and researchers because the subjective effects of psychedelics are so pronounced that both parties can usually discern whether the active substance or a placebo was administered (Nichols et al., 2017). This “unblinding” effect can introduce bias into the study results, as participants and therapists may adjust their expectations and behaviors based on their awareness of the treatment, potentially amplifying the placebo effect.

In addition to issues with placebo control, psychedelic therapy research also faces challenges related to participant variability. Psychedelic experiences are profoundly influenced by “set and setting,” which refers to the mental state of the participant and the physical and social environment in which the substance is administered. This makes it difficult to standardize treatment conditions across studies. Individual differences in personality, mental health history, and cultural background can significantly affect how participants respond to psychedelic therapy (Carhart-Harris et al., 2018). Researchers must carefully account for these variables when designing studies, but doing so adds layers of complexity to the research process, often requiring large sample sizes and multiple study sites to achieve robust and generalizable results.

Long-term Efficacy and Safety Monitoring

Another important methodological consideration in psychedelic therapy research is the need for long-term efficacy and safety monitoring. While short-term results from clinical trials have been promising, there is still limited data on the long-term effects of psychedelic treatments. Most studies follow participants for only a few months after treatment, which may not be sufficient to fully understand the durability of therapeutic benefits or the potential for adverse effects to emerge over time. For instance, while psilocybin and MDMA have shown substantial therapeutic potential in treating depression and PTSD, questions remain regarding how long the positive effects last and whether patients may require follow-up sessions to maintain their improvements (Griffiths et al., 2016). To address these concerns, researchers must implement long-term follow-up assessments that track participants for years after treatment, which poses logistical and financial challenges.

Moreover, the safety of repeated psychedelic use remains an area of concern. Although current research suggests that psychedelics are physiologically safe when used in controlled clinical settings, their psychological effects can vary greatly depending on the individual and the context of use. Adverse reactions, such as “bad trips” or anxiety attacks, are relatively rare in therapeutic settings but do occur and can have lasting psychological effects (Johnson et al., 2008). Psychedelic therapies are also contraindicated for individuals with certain psychiatric conditions, such as schizophrenia or bipolar disorder, as they may exacerbate symptoms (Schenberg, 2018). Ensuring that participants are carefully screened and that the therapies are administered by trained professionals is essential to minimizing risks. Nonetheless, further research is needed to explore the long-term psychological impact of these treatments, especially as their use becomes more widespread in clinical practice.

Ethical and Legal Challenges in Psychedelic Therapies

The rapid resurgence of psychedelic research and its therapeutic applications have raised complex ethical and legal questions. While preliminary evidence demonstrates the efficacy of psychedelic therapies for various psychological conditions, the regulatory and ethical frameworks surrounding their use are still in flux. These challenges are multifaceted, involving concerns about patient safety, informed consent, potential abuse, and the broader legal status of psychedelics as controlled substances. Understanding these challenges is essential to advancing psychedelic therapy responsibly and effectively.

Informed Consent and Patient Vulnerability

One of the foremost ethical concerns in psychedelic therapy is ensuring that patients provide fully informed consent, given the profound and often unpredictable nature of psychedelic experiences. Psychedelic therapies can induce altered states of consciousness, including hallucinations and deep emotional experiences, which can be difficult to anticipate and explain to patients beforehand (Yaden et al., 2017). This makes the process of obtaining informed consent particularly challenging. Patients must be thoroughly educated about the potential risks, benefits, and nature of the experience to make an informed decision. Unlike more conventional therapies, where the effects of the treatment are relatively predictable, psychedelic experiences vary greatly based on the individual’s psychological state, personality, and the therapeutic context.

Additionally, the vulnerability of patients undergoing psychedelic therapy raises ethical concerns. Many participants in psychedelic therapy trials suffer from severe psychological conditions such as treatment-resistant depression or PTSD, making them particularly vulnerable to exploitation or harm (Schenberg, 2018). Therapists must be especially cautious to maintain professional boundaries and ensure that the altered states induced by psychedelics do not compromise the therapeutic relationship. Careful screening of participants, rigorous protocols, and ongoing supervision of therapists are critical to ensuring that patient vulnerability is not exploited during or after the treatment.

Risk of Adverse Psychological Reactions

Another ethical challenge involves managing the risks associated with psychedelic therapy, particularly the potential for adverse psychological reactions. While psychedelics like psilocybin and MDMA have shown considerable therapeutic promise, they can also produce distressing experiences, sometimes referred to as “bad trips,” which can lead to intense anxiety, paranoia, or psychosis (Johnson et al., 2008). In rare cases, these adverse reactions can have lasting psychological effects, particularly for individuals with preexisting psychiatric conditions. Ethically, it is crucial that researchers and clinicians carefully assess the psychological stability of participants and implement safety measures, such as having trained guides present during therapy sessions, to mitigate these risks (Carhart-Harris & Goodwin, 2017).

The risk of long-term psychological effects also necessitates careful consideration of the screening processes used to select participants for psychedelic therapy. Certain individuals, such as those with a family history of schizophrenia or bipolar disorder, are generally excluded from trials due to the heightened risk of triggering psychotic episodes (Schenberg, 2018). This exclusion raises ethical questions about access to potentially life-changing therapies for people who might be at higher risk but could still benefit from controlled interventions. Developing ethical guidelines for managing these risks while expanding access to psychedelic therapies remains an ongoing challenge for the field.

Therapist-Participant Boundaries and Power Dynamics

The altered states of consciousness induced by psychedelics often lead to heightened emotional sensitivity, which can impact the therapeutic relationship. This introduces the potential for boundary violations, where the participant may become overly reliant on or emotionally attached to the therapist (Watts & Luoma, 2020). Such dynamics are particularly pronounced in psychedelic therapy because participants often experience deep emotional or mystical experiences, which can lead them to perceive the therapist as a guide or authority figure in ways that go beyond the traditional therapeutic framework. The intensity of these experiences may blur professional boundaries, making it crucial for therapists to maintain clear ethical guidelines and avoid any form of exploitation or manipulation of the patient’s vulnerable state.

Moreover, the non-ordinary states of consciousness induced by psychedelics may foster a sense of dependency or idealization of the therapist, especially when the therapy involves multiple sessions. This raises ethical concerns about maintaining professional distance and avoiding any misuse of power within the therapeutic context. Psychotherapists must undergo specialized training to navigate these dynamics and handle the unique challenges posed by psychedelic therapy responsibly (Nichols, 2016). Ensuring that all therapists are equipped to deal with these altered states ethically and maintain the integrity of the therapeutic relationship is an essential aspect of professional conduct in this emerging field.

Access and Equity in Psychedelic Therapies

As psychedelic therapies gain traction and move toward mainstream acceptance, issues of access and equity have emerged as significant ethical concerns. Psychedelic-assisted therapy is often expensive and not covered by insurance in most countries, which limits access to these treatments for lower-income individuals who may benefit most from them (Williams et al., 2021). This raises questions of distributive justice, as the potential of these therapies to address mental health issues may be disproportionately available to affluent individuals, while marginalized populations—who often bear the greatest burden of mental health disorders—are left without access.

Furthermore, the commercialization of psychedelics may exacerbate inequities in access. As psychedelic-assisted therapies become more widely available, there is a growing risk that these treatments could be commodified, leading to a system where access to potentially life-saving treatments is restricted by socioeconomic status. To address these concerns, some advocates have called for policies that ensure equitable access to psychedelic therapies, including public funding for research and therapy, and sliding scale pricing models to accommodate people from diverse economic backgrounds (George et al., 2019). Developing frameworks that promote fairness in access to psychedelic treatments is critical to ensuring that these therapies benefit a broad range of individuals rather than reinforcing existing healthcare inequities.

Legal Status and Regulatory Challenges

The legal status of psychedelics poses another significant challenge to their therapeutic use. In many countries, substances such as psilocybin, LSD, and MDMA are classified as Schedule I drugs, indicating that they are considered to have no accepted medical use and a high potential for abuse. This classification creates substantial regulatory barriers for researchers and clinicians seeking to study or administer these substances in therapeutic contexts (Nutt et al., 2013). Obtaining approval for clinical trials involving Schedule I substances requires navigating complex regulatory frameworks, which can delay research progress and limit the availability of psychedelic therapies to the public.

Efforts to reclassify psychedelics and reduce regulatory hurdles are underway, but these efforts are often met with resistance due to concerns about the potential for misuse outside of clinical settings. Public perceptions of psychedelics are still influenced by their association with countercultural movements and recreational drug use, leading to stigma and fear of liberalizing access to these substances (Nutt et al., 2020). Addressing these legal and regulatory challenges requires ongoing advocacy, education, and collaboration between researchers, policymakers, and the public to ensure that the therapeutic potential of psychedelics can be realized in a safe and controlled manner.

Addressing Cultural and Spiritual Concerns

Psychedelics have long been used in indigenous spiritual and healing practices, particularly in regions of South America where substances like ayahuasca and peyote have played central roles in religious ceremonies. The growing interest in psychedelic therapies in Western medicine raises concerns about cultural appropriation and the potential exploitation of indigenous knowledge without proper recognition or compensation (Tupper, 2008). As psychedelic research continues to advance, it is essential to engage with the communities that have historically used these substances and ensure that their perspectives are respected in the development of modern therapeutic practices.

The incorporation of spiritual elements into psychedelic therapy also raises ethical questions about the boundaries between medicine and spirituality. Many participants in psychedelic therapy report mystical or spiritual experiences that they describe as central to their healing process (Griffiths et al., 2006). While these experiences may be beneficial for some, the inclusion of spiritual elements in clinical settings can create ethical challenges, particularly in secular healthcare environments. Balancing the therapeutic value of these experiences with the need to maintain scientific rigor and respect for diverse cultural and spiritual beliefs is an ongoing ethical consideration in the field of psychedelic therapy.

Conclusion

The resurgence of interest in psychedelic therapies marks a significant evolution in the treatment landscape for various psychological conditions. Research has shown promising results, suggesting that psychedelics can facilitate profound therapeutic experiences that foster healing and transformation (Griffiths et al., 2016; Ross et al., 2016). However, as the field advances, it is imperative to navigate the ethical and legal challenges that accompany the therapeutic use of these substances. Addressing issues related to informed consent, patient vulnerability, and potential psychological risks will be crucial for establishing safe and effective treatment protocols (Schenberg, 2018; Yaden et al., 2017).

Moreover, the integration of psychedelic therapies into mainstream medical practice necessitates a thorough examination of the societal implications, including concerns about access and equity. As these therapies become more popular, it is essential to ensure that marginalized populations do not miss out on potential benefits due to socioeconomic barriers (Williams et al., 2021). Additionally, understanding the cultural contexts in which psychedelics have traditionally been used can provide valuable insights into their therapeutic applications and help prevent the appropriation of indigenous practices (Tupper, 2008). Promoting a holistic approach that values the contributions of diverse cultural perspectives will enhance the ethical foundation of psychedelic therapy.

In conclusion, while the future of psychedelic therapies holds immense potential for revolutionizing mental health treatment, the pathway forward is fraught with challenges that must be addressed proactively. Continued research, coupled with ethical vigilance and regulatory reform, is essential to realize the full therapeutic potential of psychedelics while safeguarding patient welfare and promoting equitable access. As the scientific community, policymakers, and society at large engage in these discussions, a balanced and responsible approach will be vital in ensuring that psychedelic therapies are harnessed safely and effectively to improve mental health outcomes for all.

Bibliography

1. Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.
2. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 42(11), 2105-2113.
3. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., … & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. The Lancet Psychiatry, 3(7), 619-627.
4. Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725-731.
5. Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157-164.
6. George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2019). The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies, 3(3), 122-132.
7. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.
8. Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283.
9. Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic drugs reconsidered. Basic Books.
10. Hofmann, A. (2013). LSD: My problem child. Multidisciplinary Association for Psychedelic Studies.
11. Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., … & Doblin, R. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology, 237(8), 2485-2497.
12. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.
13. Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2019). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166.
14. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.
15. Labate, B. C., & Cavnar, C. (2014). Ayahuasca shamanism in the Amazon and beyond. Oxford University Press.
16. Ly, C., Greb, A. C., Cameron, L. P., Wong, E. W., Barragan, E. V., Wilson, P. C., … & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182.
17. Metzner, R. (2017). Sacred mushroom of visions: Teonanácatl: A sourcebook on the psilocybin mushroom. Inner Traditions/Bear & Co.
18. Mithoefer, M. C., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, E., … & Doblin, R. (2018). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 235(8), 2735-2745.
19. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452.
20. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.
21. Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology & Therapeutics, 101(2), 209-219.
22. Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020). Psychedelic psychiatry’s brave new world. Cell, 181(1), 24-28.
23. Nutt, D., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 14(8), 577-585.
24. Pollan, M. (2018). How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin Press.
25. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … & Corby, P. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.
26. Schenberg, E. E. (2018). Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology, 9, 733.
27. Tupper, K. W. (2008). The globalization of ayahuasca: Harm reduction or benefit maximization? International Journal of Drug Policy, 19(4), 297-303.
28. Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15, 92-102.
29. Williams, M. T., Reed, S., & George, J. (2021). Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists. Journal of Psychedelic Studies, 4(3), 152-161.
30. Yaden, D. B., Haidt, J., Hood, R. W., Vago, D. R., & Newberg, A. B. (2017). The varieties of self-transcendent experience. Review of General Psychology, 21(2), 143-160.